| 1 |
34964902 | Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. | 2021 Dec 29 |
1 |
| 2 |
31490549 | IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer. | 2020 Apr 15 |
1 |
| 3 |
32373071 | Targeted Gene Expression Profile Reveals CDK4 as Therapeutic Target for Selected Patients With Adrenocortical Carcinoma. | 2020 |
1 |
| 4 |
31480400 | Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. | 2019 Aug 30 |
1 |
| 5 |
29731738 | Insulin-Like Growth Factor 2 mRNA-Binding Protein 3 Influences Sensitivity to Anti-IGF System Agents Through the Translational Regulation of IGF1R. | 2018 |
1 |
| 6 |
28760855 | Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. | 2017 Sep 15 |
3 |
| 7 |
26561558 | InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma. | 2016 Apr 1 |
1 |
| 8 |
26831715 | Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. | 2016 Jun 15 |
1 |
| 9 |
27200287 | Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR. | 2016 |
1 |
| 10 |
25212606 | A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. | 2015 Feb 15 |
2 |
| 11 |
25795408 | Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. | 2015 Apr |
1 |
| 12 |
22932796 | Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. | 2012 Oct 18 |
1 |
| 13 |
20924128 | Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. | 2010 Oct |
1 |
| 14 |
21425998 | Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. | 2009 Sep |
1 |